Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison
- DOI
- 10.3390/bioengineering13070789
- Published
- 2026-07-09
- Container
- Bioengineering
- Publisher
- MDPI AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3390/bioengineering13070789,
title = {Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison},
author = {Jeong-Gyu Choi and Eun Jeong Gong and Chang Seok Bang and Jae Jun Lee},
year = {2026},
journal = {Bioengineering},
doi = {10.3390/bioengineering13070789},
url = {https://doi.org/10.3390/bioengineering13070789}
}RIS
TY - JOUR TI - Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison AU - Jeong-Gyu Choi AU - Eun Jeong Gong AU - Chang Seok Bang AU - Jae Jun Lee PY - 2026 JO - Bioengineering DO - 10.3390/bioengineering13070789 UR - https://doi.org/10.3390/bioengineering13070789 ER -
APA
Choi, J., Gong, E. J., Bang, C. S., & Lee, J. J. (2026). Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison. Bioengineering. https://doi.org/10.3390/bioengineering13070789
Source records
- crossref · retrieved 2026-09-27T11:19:54.403Z